Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2′,3′-dideoxy-5-fluoro-3′-thiacytidine [FTC]), and tenofovir alafenamide (Taf) has been recently approved by the European Medicines Agency for the treatment of HIV infection, and is the first ever protease-inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Squillace, Nicola, Bozzi, Giorgio, Colella, Elisa, Gori, Andrea, Bandera, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211373/
https://www.ncbi.nlm.nih.gov/pubmed/30464395
http://dx.doi.org/10.2147/DDDT.S147493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211373/
https://www.ncbi.nlm.nih.gov/pubmed/30464395
http://dx.doi.org/10.2147/DDDT.S147493

Ejemplares similares